4/A: Brainstorm Cell Therapeutics CEO Corrects Transaction Code in Form 4 Amendment

Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous Form 4 to correct an administrative error regarding the transaction code for a common stock purchase.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics, filed an amended Form 4 with the SEC on July 31, 2024.
• The amendment corrects an error in the original Form 4 filed on May 7, 2024, which incorrectly listed the transaction code as 'A' instead of 'P'.
• The corrected form indicates that Mr. Lebovits purchased 66,300 shares of common stock at a weighted average price of $0.3743 on May 7, 2024.
• Following the reported transaction, Mr. Lebovits directly owns 1,059,865 shares and may be deemed the beneficial owner of 2,000,847 indirectly owned shares.
• The indirectly owned shares include 1,933,794 shares held by ACCBT Corp. and 67,053 shares held by ACC International Holdings Ltd.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing to correct an administrative error. It doesn't indicate any fundamental changes in the company's financial health or prospects, but transparency is generally viewed positively.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's securities, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The correction of the transaction code ensures accurate information for shareholders and potential investors.

Key Dates

Keywords

Form 4, Amendment, SEC, Chaim Lebovits, Brainstorm Cell Therapeutics, BCLI, Common Stock, Beneficial Ownership, Transaction Code